Plain-English translation of NCT05531565 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can reduce skin symptoms in people with cutaneous lupus erythematosus—a form of lupus that primarily affects the skin. The medication works by targeting specific immune cells involved in the disease. Researchers are comparing the medication to a placebo (a dummy injection with no active ingredient) to see if it really helps.
Many people with cutaneous lupus don't respond well to or can't tolerate the standard medications (antimalarials) that are typically prescribed first. This trial exists to find a new treatment option for those patients who need other solutions.
Participants receive subcutaneous injections (shots under the skin) every 4 weeks for about 5 months during the main treatment phase, plus an extra dose at week 2. Half the participants will receive the new medication while the other half receive placebo, though neither they nor the researchers will initially know which they're getting. The study continues for up to a year total, with follow-up visits to measure how well the skin symptoms improve and to monitor for any side effects.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States